Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 mrt 2016 - 08:21
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug Reports Full Year 2015 Financial Results
Bericht
Probiodrug reports full year 2015 financial results
Phase 2a study of novel treatment for Alzheimer's disease initiated
Phase 1 PQ912 data, a first in class Glutaminyl Cyclase (QC) inhibitor for the treatment of AD, prominently published
Private Placement completed raising EUR 13.5 million
HALLE/SAALE, Germany, 15 March 2016 Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced its financial results for the twelve-month period ending 31 December 2015 prepared in accordance with German GAAP ("HGB") and, on a voluntary basis, in accordance with IFRS as endorsed by the European Union. The Annual Reports are available on the company website (http://www.probiodrug.de/investors/reports-and-presentations/).
Datum laatste update: 01 september 2024